Hemophilia Classification by Factor VIII Levels
Hemophilia is classified into three severity categories based on plasma Factor VIII (or Factor IX) activity levels: severe (<1% of normal), moderate (1-5% of normal), and mild (>5-40% of normal), which generally correlates with clinical bleeding patterns 1, 2.
Classification System
The International Society on Thrombosis and Haemostasis (ISTH) established and reaffirmed this classification system, which remains the standard approach despite recognized limitations 1.
Severity Categories:
Severe Hemophilia: Factor VIII <1 IU/dL (<1% of normal)
- Spontaneous bleeding episodes, particularly into joints and muscles
- Bleeding occurs without obvious trauma
- Most frequent sites: hemarthroses (joint bleeds) and muscle hemorrhages
- Typically presents in early childhood
- Without prophylaxis, patients experience frequent spontaneous bleeds 2
Moderate Hemophilia: Factor VIII 1-5 IU/dL (1-5% of normal)
- Intermediate bleeding phenotype
- Primarily trauma-induced bleeding, though some spontaneous bleeds may occur
- Clinical presentation can sometimes mimic severe hemophilia
- Less predictable bleeding pattern than severe disease 2
Mild Hemophilia: Factor VIII >5-40 IU/dL (>5-40% of normal)
- Bleeding typically occurs only with surgery, dental procedures, or significant trauma
- Rarely experience spontaneous bleeding
- May remain undiagnosed until adulthood or after surgical challenge
- Generally do not require prophylactic treatment 2
Clinical Presentation Correlation
Important Caveats:
The ISTH explicitly acknowledges that this laboratory-based classification has significant limitations 1:
- Clinical heterogeneity exists within severity categories, particularly in severe hemophilia where 10-15% of patients demonstrate a milder bleeding phenotype despite Factor VIII levels <1%
- Identical factor levels do not guarantee identical bleeding patterns between patients
- The classification fails to account for individual bleeding phenotype variability
Factors Contributing to Phenotypic Variability:
While the guidelines maintain the factor level-based classification, recognize that bleeding severity is influenced by:
- Specific F8 gene mutations
- Genetic modifiers in other hemostasis genes
- Inflammatory and immune response variations
- Environmental factors
- Age and joint disease status
Gray Zone:
The classification of individuals with Factor VIII levels between 40-50% remains unresolved and may require future guideline updates 1.
Clinical Application
Despite the recognized heterogeneity, the factor level-based classification remains the standard because it correlates well with clinical profiles in most cases and provides a practical framework for treatment decisions 1. However, treatment intensity (particularly prophylaxis decisions) should consider both laboratory severity and actual bleeding phenotype, as some patients with "moderate" levels by laboratory criteria may exhibit severe bleeding patterns requiring more aggressive management 2.
The guidelines emphasize that this classification system, while imperfect, provides essential standardization for clinical care documentation, treatment protocol comparison, and clinical trial design 1.